Cytogen Valuation
| 217330 Stock | KRW 4,330 70.00 1.64% |
At this time, the firm appears to be overvalued. Cytogen shows a prevailing Real Value of W4155.9 per share. The current price of the firm is W4330.0. Our model approximates the value of Cytogen from analyzing the firm fundamentals such as Operating Margin of (9.92) %, return on equity of -96.72, and Shares Outstanding of 5.63 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cytogen's price fluctuation is very steady at this time. Calculation of the real value of Cytogen is based on 3 months time horizon. Increasing Cytogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cytogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cytogen Stock. However, Cytogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4330.0 | Real 4155.9 | Hype 4330.0 | Naive 3927.44 |
The real value of Cytogen Stock, also known as its intrinsic value, is the underlying worth of Cytogen Company, which is reflected in its stock price. It is based on Cytogen's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cytogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cytogen helps investors to forecast how Cytogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cytogen more accurately as focusing exclusively on Cytogen's fundamentals will not take into account other important factors: Cytogen Total Value Analysis
Cytogen is presently forecasted to have takeover price of 324.23 B with market capitalization of 95.89 B, debt of 20.9 B, and cash on hands of 30.29 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cytogen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
324.23 B | 95.89 B | 20.9 B | 30.29 B |
Cytogen Investor Information
About 39.0% of the company shares are owned by insiders or employees . The company had not issued any dividends in recent years. Cytogen had 3:1 split on the 28th of September 2022. Based on the analysis of Cytogen's profitability, liquidity, and operating efficiency, Cytogen is not in a good financial situation at the moment. It has a very high risk of going through financial straits in March.Cytogen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cytogen has an asset utilization ratio of 0.63 percent. This suggests that the Company is making W0.006264 for each dollar of assets. An increasing asset utilization means that Cytogen is more efficient with each dollar of assets it utilizes for everyday operations.Cytogen Ownership Allocation
The market capitalization of Cytogen is W95.89 Billion. Cytogen retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Cytogen Profitability Analysis
The company reported the revenue of 347.85 M. Net Loss for the year was (10.87 B) with loss before overhead, payroll, taxes, and interest of (129.63 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cytogen's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cytogen and how it compares across the competition.
About Cytogen Valuation
The stock valuation mechanism determines Cytogen's current worth on a weekly basis. Our valuation model uses a comparative analysis of Cytogen. We calculate exposure to Cytogen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cytogen's related companies.Cytogen, Inc., a biotechnology company, develops and sells CTC enrichment and downstream systems to treat cancer in South Korea. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea. Cytogen is traded on Korean Securities Dealers Automated Quotations in South Korea.
8 Steps to conduct Cytogen's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cytogen's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cytogen's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Cytogen's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Cytogen's revenue streams: Identify Cytogen's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Cytogen's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Cytogen's growth potential: Evaluate Cytogen's management, business model, and growth potential.
- Determine Cytogen's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cytogen's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Cytogen Stock analysis
When running Cytogen's price analysis, check to measure Cytogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytogen is operating at the current time. Most of Cytogen's value examination focuses on studying past and present price action to predict the probability of Cytogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytogen's price. Additionally, you may evaluate how the addition of Cytogen to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |